Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELP Study: Levosimendan in PH-HFpEF
NCT03541603Phase 2Completed
- Sponsor
- Tenax Therapeutics
- Start
- Nov 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) comparing Levosimendan with Placebo (2 arms). Primary endpoint: Change From Baseline Pulmonary Capillary Wedge Pressure (PCWP) With Bicycle Exercise at 6 weeks. Started Nov 2018; status: completed.
02
Drugs
levosimendan
03
Conditions
pulmonary hypertension (PH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03541603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541603.